本文へ移動
AiSeekAiSeek
サインイン

企業

Innovent

フォロー構造マップを開くこれについて質問この企業をリサーチ

Innovent の構造

Innovent

企業

関連 7 件
同業競合と提携
関係の開始2026
Innovent企業 · 関連 7 件
第 1 層

同業競合と提携7

関係

矢印は関係の方向を示します。分野で絞り込めます。

  • Innoventと提携 →Eli Lilly
    企業 · Eli Lilly根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る
  • Innoventと提携 →Roche
    企業 · Roche根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る
  • Innoventと提携 →Takeda
    企業 · Takeda根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る
  • Innoventと提携 →Pfizer
    企業 · Pfizer根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る
  • Innoventと提携 →Sanofi
    企業 · Sanofi根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る
  • Innoventと提携 →Incyte
    企業 · Incyte根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る
  • Innoventと提携 →MD Anderson Cancer Center
    組織 · MD Anderson Cancer Center根拠 1
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-09
      Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
      出典を見る

7 件中 1 から 7 件を表示

主張

出典とともに結論を確認し、項目を開いて証拠を読めます。

事実根拠 1
products launched in the market20 products

Innovent has launched 20 products in the market.

PR Newswire news releases · 2026-10-09

証拠を見る
  • 企業開示PR Newswire news releases2026-10-09
    Innovent has launched 20 products in the market.
    出典を見る
事実根拠 1
assets under nda review1 asset

It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.

PR Newswire news releases · 2026-10-09

証拠を見る
  • 企業開示PR Newswire news releases2026-10-09
    It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.
    出典を見る
事実根拠 1
assets in phase 3 or pivotal clinical trials5 assets

It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.

PR Newswire news releases · 2026-10-09

証拠を見る
  • 企業開示PR Newswire news releases2026-10-09
    It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.
    出典を見る
事実根拠 1
molecules in early clinical stage19 molecules

It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.

PR Newswire news releases · 2026-10-09

証拠を見る
  • 企業開示PR Newswire news releases2026-10-09
    It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.
    出典を見る
事実根拠 1
と提携Eli Lilly

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.

PR Newswire news releases · 2026-10-09

証拠を見る
  • 企業開示PR Newswire news releases2026-10-09
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
    出典を見る
事実根拠 1
と提携Roche

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.

PR Newswire news releases · 2026-10-09

証拠を見る
  • 企業開示PR Newswire news releases2026-10-09
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
    出典を見る

11 件中 1 から 6 件を表示

市場とバリュエーション

バリュエーションは Pro と Research で利用できます。

Pro で解放

利用できません: 企業シグナル · 財務 · 開示資料 · ガイダンス